Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

BACKGROUND: Gemcitabine/nab-paclitaxel and FOLFIRINOX demonstrated significantly increased survival compared with gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): objective response rate (ORR) 23 and 31.6%, progression-free survival (PFS) 5.5 and 6.4 months, overall survival (OS) 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruera, Gemma, Massacese, Silvia, Candria, Stefania, Galvano, Antonio, Manetta, Rosa, Giordano, Aldo Victor, Carducci, Sergio, Di Sibio, Alessandra, Ciacco, Eugenio, Russo, Antonio, Ricevuto, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112758/
https://www.ncbi.nlm.nih.gov/pubmed/30159128
http://dx.doi.org/10.18632/oncotarget.25870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112758/
https://www.ncbi.nlm.nih.gov/pubmed/30159128
http://dx.doi.org/10.18632/oncotarget.25870

Ejemplares similares